Access Scientific Completes Study Demonstrating Superior Anti-Thrombotic Properties of POWERWAND Midlines and Extended Dwell Catheters

Register to receive a free Vascular Access Devices and Accessories Market Report Suite for US 2018-2024 synopsis and brochure

Access Scientific, LLC announced the completion of an in vivo study demonstrating the superior anti-thrombotic (i.e., anti-clotting) property of its unique intravascular catheter material, ChronoFlex C® with BioGUARD™ technology.

The study found that ChronoFlex C with BioGUARD demonstrates thrombo-resistance where it matters most — on the surface of the blood vessel. No other catheter material has demonstrated this clinically important effect.

While other catheter manufacturers claim anti-thrombotic properties that reduce thrombus (clot) formation “on the surface of the catheter,” these anti-thrombotic claims cite in vivo or in vitro studies that show diminished thrombus formation solely on the surface of the catheter. This finding is often and mistakenly conflated with deep vein thrombosis (DVT) – a condition known to be associated with high-risk complications like bloodstream infection or blood clot embolization. There is no evidence that thrombo-resistance on the surface of the catheter has any effect on diminishing DVTs in actual patients.

This announcement may serve to explain, at least in part, why Access Scientific’s POWERWAND™ catheters consistently demonstrate fewer DVTs and fewer total complications (including bloodstream infections) than other catheters used for similar purposes. “We now know it is not just the POWERWAND atraumatic insertion techniques that allow the vessel lining to remain clean and smooth,” said Steve Bierman MD, the company’s Chief Medical Officer. “It is also the catheter material, ChronoFlex C, and our patented BioGUARD processing, that makes POWERWAND anti-thrombotic both on the catheter surface and on the vessel wall.”

As hospitals continue to face the pressures of Value-Based Purchasing, novel products like POWERWAND offer solutions that both improve patient outcomes and reduce overall costs.

Access Scientific said that in the coming months it will reveal the results of another completed study (pending publication). Combined with the current announcement of superior anti-thrombogenicity, this next study demonstrates the value of ChronoFlex C with BioGUARD as the ideal material for a wide variety of indwelling vascular catheters.

About Access Scientific, LLC 

Access Scientific, LLC, based in San Diego, Calif., is an evidence-based, infection prevention company offering innovative vascular access devices designed to reduce the need for and risk of vascular device-related complications, including bloodstream infections.


For Further Information

More on the vascular access device market in the U.S. can be found in a series of reports published by iData Research, entitled the U.S. Market Report Suite for Vascular Access Devices and Accessories 2018. The U.S. market for vascular access devices and accessories includes implantable ports, port needles, central venous catheters (CVCs), peripherally inserted central catheters (PICCs), peripheral intravenous catheters (PIVCs), midlines, dialysis catheters, ultrasound systems, tip guidance devices, catheter securement devices, syringes, and needles.

The iData report series on vascular access devices covers the U.S., Brazil, South Korea, Japan, Australia, China, India, and 15 countries in Europe including Germany, France, the United Kingdom (U.K.), Italy, Spain, Benelux (Belgium, Netherlands, and Luxembourg), Scandinavia (Finland, Denmark, Sweden, and Norway), Portugal, Austria, and Switzerland. Reports provide a comprehensive analysis including units sold, market value, forecasts, as well as detailed competitive market shares, and analysis of major players’ success strategies in each market and segment. To find out more about vascular access device market data, register online or email us at for the U.S. Market Report Suite for Vascular Access Devices and Accessories 2018 brochure and synopsis.

Leave a Reply